Tag Archives: DCTs

Harsha Rajasimha, Ph.D.

AI and the Lack of Diversity in Data: Implications and the Path Forward for Rare Disease Research

By MedTech Intelligence Staff
Harsha Rajasimha, Ph.D.

Genomics data scientist Harsha Rajasimha, Ph.D., Founder and Executive Chairman of IndoUSrare, highlights the risks of developing AI/ML algorithms based on biased data, as well as efforts underway to improve global collaboration on the collection and sharing of health data that may help us realize the potential of AI in diagnoses and treatment of rare diseases.

Continue reading

Khan and Maloney

Decentralized Clinical Trials: Considerations for Implementation

By Myla Maloney, MBA, BCMAS, Yosef Khan, MD, MPH, PhD
Khan and Maloney

Randomized clinical trials are the gold standard for conducting clinical research. They are, however, fraught with issues and come with burdens to the patient, site and sponsor. Decentralized trials (DCTs) allow for a novel, agile and more cost-effective approach to an industry standard and traditional methodology. Here’s how to determine if a full or hybrid DCT is a good option for your clinical trial.

Continue reading